Sigachi Industries is set to commence Research & Development (R&D) operations on July 28, 2025 at its newly established R&D Center in Hyderabad, with a focus on developing a high-value pipeline of Active Pharmaceutical Ingredients (APIs) targeted for global markets. Positioned as a critical pillar of the company’s innovation strategy, this R&D Center will drive end-to-end API development from lab-scale innovation to commercialization and global regulatory filings.
Sigachi Industries is an industry leader in the field of Pharma Excipients, Nutra and food ingredients. The company has rapidly established itself as one of the largest manufacturers of Microcrystalline Cellulose worldwide.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: